<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
August 15, 2000
Date of Report (Date of earliest event reported):
SUPERGEN, INC.
---------------
(Exact name of registrant as specified in its charter)
DELAWARE 0-27628 91-1841574
-------- ------- ----------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification No.)
incorporation)
TWO ANNABEL LANE, SUITE 220, SAN RAMON, CALIFORNIA 94583
-------------------------------------------------- -----
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (925) 327-0200
<PAGE>
ITEM 5. OTHER EVENTS
On August 15, 2000, we announced the appointment of Karl L. Mettinger,
M.D., Ph.D., as Senior Vice President, Clinical Research and Medical Affairs;
Lawrence A. Romel as Vice President, Clinical Operations; and Jorge F.
DiMartino, M.D., Ph.D. as Associate Director, Clinical Research. On August 17,
2000, we announced the appointment of Charlene P. Holt, M.D. as Medical Director
of Commercial Operations; the resignation of Rajesh C. Shrotriya, M.D. as
Executive Vice President and Chief Scientific Officer; and the retirement of
Luigi Lenaz, M.D. as Senior Vice President and Medical Director.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits
99.1 Press release dated August 15, 2000.
99.2 Press release dated August 17, 2000
----------------------------
-2-
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
SUPERGEN, INC.
Date: August 17, 2000 By: /s/ Ronald H. Spair
-------------------------------
Ronald H. Spair
Senior Vice President and
Chief Financial Officer
-3-
<PAGE>
EXHIBIT INDEX
Exhibit No. Description
----------- -----------
99.1 Press release dated August 15, 2000.
99.2 Press release dated August 17, 2000.
-4-
